genflow

Background

Genflow Biosciences Plc, established in 2020, is a UK-based biotechnology company with research and development facilities in Belgium. The company is dedicated to pioneering gene therapies aimed at decelerating the aging process, thereby promoting longer and healthier lives. By focusing on the SIRT6 gene—a variant associated with longevity found in centenarians—Genflow seeks to mitigate the financial, emotional, and social impacts of a rapidly aging global population.

Key Strategic Focus

Genflow's strategic focus centers on developing gene therapies that target age-related diseases by leveraging the SIRT6 gene variant. The company's core objectives include advancing its lead compound, GF-1002, for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), a prevalent chronic liver disease lacking effective treatments. Additionally, Genflow is exploring therapies for Werner Syndrome, a condition causing premature aging, and sarcopenia, an age-related muscle loss disorder. The company employs proprietary technologies and collaborates with specialized partners to enhance its research and development capabilities.

Financials and Funding

In January 2021, Genflow secured an $11 million investment from UK investor BGF to scale its operations and support international expansion. In April 2024, the company raised £715,000 through a placing and subscription of new ordinary shares, with participation from all directors, including CEO Dr. Eric Leire, who personally invested £50,000. These funds are intended to advance the development of Genflow's gene therapy programs and support ongoing research initiatives.

Pipeline Development

Genflow's pipeline includes several key candidates:

• GF-1002 (MASH): Advancing to the pre-Investigational New Drug (IND) phase, with plans to initiate a proof-of-concept clinical trial in 2025.

• GF-1003 (Werner Syndrome): Development of a proprietary liver organoid model derived from human cells of patients with Werner syndrome, allowing for direct testing of the drug candidate in a disease-relevant human tissue model.

• GF-1004 (Dog Aging): Initiated a life extension clinical trial for aging dogs in collaboration with Syngene, with full analysis expected by the end of 2025.

• GF-1005 (Sarcopenia): Progressing with myoblast progenitor cells engineered to express the centenarian variant of SIRT6, in collaboration with Université libre de Bruxelles and Revatis.

Technological Platform and Innovation

Genflow's innovation is anchored in its proprietary gene therapy platform centered on the SIRT6 gene variant. This platform involves:

• Proprietary Technologies: Development of gene therapies delivering the centenarian variant of SIRT6 to target tissues, aiming to enhance DNA repair and metabolic functions associated with aging.

• Scientific Methodologies: Utilization of advanced organoid models derived from patient cells to test drug candidates, reducing reliance on animal models and providing more accurate human-specific data.

• AI-Driven Capabilities: Collaboration with Heureka Labs to apply artificial intelligence in analyzing complex genomic data, enhancing therapeutic design and patient-specific outcome predictions.

Leadership Team

Genflow's leadership comprises experienced professionals:

• Dr. Eric Leire, Founder & CEO: Brings extensive biotechnology expertise from roles in pharmaceutical companies like Pfizer and Schering Plough, and leadership positions in various biotech firms.

• Dr. Cedric Szpirer, Head of CMC: Holds a PhD in molecular biology and founded Delphi Genetics in 2001, serving as Executive & Scientific Director.

• Tamara Joseph, Chairperson: A seasoned healthcare leader with extensive experience in early-stage and commercial biotech companies in the US and other markets.

• Dr. Guy Charles Fanneau de la Horie, Non-Executive Director: Over 20 years of experience leading biotech executive teams, successfully leading IPOs and strategic partnerships.

• Dr. Peter King-Lewis, Non-Executive Director: Studied Medicine at St Bartholomew’s Hospital in London, with prior service as a Submarine Seaman Officer and Diver in The Royal Navy.

• Dr. Yassine Bendiabdallah, Non-Executive Director: Functional Medicine Healthy Ageing Specialist and expert in Bio-identical Hormone therapy, with a background in anti-cancer drug discovery.

Leadership Changes

In 2023, Genflow expanded its Scientific Advisory Board by appointing experts such as Prof. Dr. Sven Francque, a specialist in nonalcoholic fatty liver disease, and Prof. Dr. Mary E. Rinella, an expert in fatty liver disease.

Competitor Profile

Market Insights and Dynamics:

The global anti-aging therapeutics market is experiencing significant growth, driven by increasing life expectancy and a rising prevalence of age-related diseases. Advancements in biotechnology and a growing focus on extending healthspan contribute to the market's expansion.

Competitor Analysis:

Key competitors in the longevity and gene therapy space include:

• Calico Life Sciences: A Google-backed research and development company focusing on understanding the biology of aging and developing interventions.

• Unity Biotechnology: Develops therapeutics to slow, halt, or reverse age-related diseases, with a focus on cellular senescence.

• BioAge Labs: Utilizes a systems biology approach to identify and develop drug targets for aging-related diseases.

These companies employ various technologies, including gene therapy, small molecules, and biologics, to target aging mechanisms and age-related diseases.

Strategic Collaborations and Partnerships

Genflow has established significant collaborations to bolster its research and development efforts:

• Exothera SA: Partnered for Good Manufacturing Practice (GMP) manufacturing of GF-1002, leveraging Exothera's expertise in viral vector production.

• Heureka Labs: Engaged to apply AI technology for analyzing complex genomic data, enhancing therapeutic design and patient-specific outcomes.

• CER Groupe: Signed a Master Service Agreement to provide a robust R&D framework supporting pre-IND gene therapy programs.

Operational Insights

Genflow's strategic positioning involves:

• Differentiation: Focusing on the SIRT6 gene variant, a unique approach in the longevity space, aiming to address unmet needs in age-related diseases.

• Market Position: As the only publicly listed longevity company in Europe, Genflow leverages its status to attract investment and partnerships.

• Competitive Advantages: Combining proprietary gene therapy technologies with strategic collaborations enhances its capability to advance therapies from research to clinical stages efficiently.

Strategic Opportunities and Future Directions

Genflow's roadmap includes:

• Clinical Trials: Initiating proof-of-concept studies for GF-1002 in MASH patients and GF-1004 in aging dogs, with results expected by the end of 2025.

• Pipeline Expansion: Advancing GF-1003 for Werner Syndrome and GF-1005 for sarcopenia, exploring additional indications for its gene therapy platform.

• Regulatory Engagement: Engaging with regulatory agencies to secure Orphan Drug Designation for GF-1003 targeting Werner Syndrome.

• Intellectual Property: Expanding its global IP portfolio to protect its proprietary technologies and therapeutic candidates.

By leveraging its current strengths and strategic partnerships, Genflow aims to advance its mission of developing therapies that promote longevity and address age-related diseases.

Contact Information

• Website: www.genflowbio.com

• LinkedIn: Genflow Biosciences

• Twitter: @GenflowBio